Based on its current operating plans, Rhythm expects that its cash, cash equivalents and short-term investments as of June 30, 2025, combined with the net proceeds from the July 2025 offering, will be sufficient to fund the Company’s planned operations for at least 24 months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Strong Future Performance and Market Adoption Drive Buy Rating for Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Advances in Hypothalamic Obesity Treatment with LB54640 Study
- Rhythm Pharmaceuticals’ Promising Phase 2 Study on LB54640 for Hypothalamic Obesity
- Rhythm Pharmaceuticals price target raised to $105 from $92 at Canaccord
- Promising Potential of Rhythm Pharmaceuticals’ Treatments for Hypothalamic Obesity Drives Buy Rating